eli lilly and company zepbound - Search News

News

Eli Lilly's Share Price Sheds Some Weight

CBS News on MSN · 12h

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Seeking Alpha · 13h

Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.

MarketWatch on MSN · 15h

Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

17h

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Pharmaceutical Technology on MSN18h

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

16h

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

1d

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

3don MSN

Eli Lilly and Company (LLY) Slid Despite Strong Top-Line Growth

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results